DOCSLIB.ORG

Annual Report © 2018 Ciberned

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Report © 2018 Ciberned 2018 ANNUAL REPORT © 2018 CIBERNED Coordination and management of content: Miguel Medina Padilla José de Arriba-Enríquez Aina Frontera Sánchez Almudena Flores Junquera Soledad Valero Rodríguez Design and editorial coordination: OnAccent.com CIBERNED 2018 ANNUAL REPORT INDEX 005 | Letter from the Scientific Director 006 | Introduction 009 | Aims 010 | Directory of research groups and associated institutions 012 | Geographic distribution of CIBERNED research groups 013 | Organizational structure 014 | Organization chart 015 | External scientific advisory committee 016 | Consortium members 017 | Research programmes 019 | Program 1: Alzheimer’s disease and other degenerative dementias 107 | Program 2: Parkinson’s and Huntington’s disease and other degenerative movement disorders 219 | Program 3: Amyotrophic Lateral Sclerosis and other neuromuscular disorders 257 | Cooperative research 279 | International relations 291 | Scientific productivity and other activities 307 | Finantial report 333 | Index of investigators 3 4 CIBERNED 2018 ANNUAL REPORT Jesús Ávila de Grado SCIENTIFIC DIRECTOR LETTER FROM THE SCIENTIFIC DIRECTOR As in previous years, I would like to begin by highlighting the excellent work of the re- search groups that make up CIBERNED and that has allowed us, once again, to be at the forefront of the Centers in biomedical research regarding the quality of publications in high- impact index scientific journals. In order to carry out this work, we have counted on the help and collaboration of the Management Office and the Steering Committee of the Center, as well as its support staff, and the help of the Carlos III Institute of Health and the Associated Institutions. A very important novelty has been the incorporation of six new research groups to CIBERNED, led by Drs. Boada, Mir, Acevedo, Paradas, Ostas and Martínez, to whom I want to welcome to our Center, hoping and wishing, as the groups that preceded them, to carry out a rigorous, efficient and quality work. During this year, 24 scientific papers have been published with an impact index greater than 20 in journals such as the New England Journal of Medicine, Nature, Science, Nature Medicine or Lancet Neurology, and 59 papers with an index greater than 10. In addition, 10 patents remain active, two clinical guidelines have been published and 85 clinical trials are in progress. In addition, courses and seminars have been organized, and the Training Plan has continued as planned. Due to the quality of the scientific activity carried out, some of our researchers have received awards and mentions at international and national level, so on behalf of the Center, I would like to congratulate them. Finally, I would like to highlight the success of our last Congress in Santiago de Composte- la, carried out with the invaluable help of Dr. Labandeira and the collaboration of the CIEN and Queen Sofia Foundations. We continue to progress properly. Thank you all. 5 INTRODUCTION Biomedical Research Network Centers are created to promote research excellence in Bio- medicine and Health Sciences, which is carried out in the National Health System and the Science and Technology System. Behind this initiative is the purpose of generating large Translational Research Centers, of multidisciplinary and multi-institutional nature where basic, clinical and epidemiological research can be integrated, in order to develop a sin- gle common research program, focused on certain pathologies that are relevant for the National Health System due to its prevalence or that are considered strategic because of its social impact. The genesis of CIBERNED was conducted through a coordination research strategy of ex- ploiting synergies between the different groups involved in biomedical research in these areas. It seeks to promote quality research in neurodegenerative diseases being carried out within the National Health System and the Science and Technology System through the development and promotion of a Network Research structures. The goal is to promote and finance, through the Carlos III Institute of Health, Centers for Biomedical Research in the Network (CIBER) through the association of research groups, linked to the National Health System, that contribute to scientifically substantiate the programs and policies of the National Health System in the priority areas of the National R+D+I Plan. CIBERNED was In particular, the Network Center for Biomedical Re- born with the search in Neurodegenerative Diseases (CIBERNED) was born in 2006 as the heir of the Center for Re- aim of combating search in Neurological Diseases (CIEN), which to- neurodegenerative gether with the CNIO, CNIC or CNMVIS constituted the four Centers created with the mission of fight- diseases ing the most prevalent health problems of Span- ish society: cancer, cardiovascular diseases, infectious diseases and neurodegenerative disorders. As for the other Centers, a supporting foundation named CIEN Foundation was created in 2003 as the CIEN’s management body, although unlike the other Centers, it was created as the first Network Center in Spain, eventually being renamed as CIBERNED. Since 2007 the CIEN Foundation has its headquarters in the Alzheimer Center of the Reina Sofia Foundation, created with the collaboration of CIBERNED and the CIEN Foundation, and located in Vallecas (Madrid). CIBERNED was founded under the auspices of the Carlos III Institute of Health, under a co- operation agreement signed by the Government and other participating institutions with 6 CIBERNED 2018 ANNUAL REPORT the idea of creating a Research Center in which basic, clinical and population-based stud- ies are integrated in order to develop a single joint research program, focusing on certain pathologies of great importance for the National Health System either for its prevalence or because of its social impact. It has a multidisciplinary and multi-institutional character and it is aimed at boosting the impact of cutting research in neurodegenerative disorders through a Network Research Structure, thus contributing to scientifically substantiate the programs and policies of the National Health System in the priority areas of the Na- tional R+D+I Plan. CIBERNED is a research organism, endowed with legal status under the Article 6.5 of Law 30/1992 of November 26 on the Legal Regime of Public Administrations and Common Administrative Procedure. It is formed by the association of research groups, with no physical contiguity, belonging to different administrations, institutions and regional gov- ernments, from public and private sectors with research lines and goals focused on the specific common area of neurodegenerative diseases and being coordinated to achieve scientific objectives that could hardly be considered in a more restricted execution con- text. CIBERNED is governed in the internal operating rules, by way of a Regulation. Currently, the CIBERNED-CIEN Foundation CIBERNED is partnership is the only research center in made up of research Spain (and one of the few in the world) in- groups with lines and tegrated into the international network of Centres of Excellence in Neurodegeneration objectives focused on (COEN), an initiative arising from the Euro- neurodegeneration pean Union Joint Programme for Research in Neurodegenerative Diseases (JPND). This joint program constitutes an innovative collaborative research initiative created to ad- dress the growing challenges posed by this group of diseases. Its goal is to boost the impact of research by aligning existing national research programs and identifying the common objectives whose scope would benefit through joint action. Its own statutes govern CIBERNED and since the end of 2018 its activity is structured around two Scientific Programs: • Program 1: Alzheimer’s disease and other degenerative dementias. • Program 2: Parkinson’s and Huntington’s disease and other degenerative movement disorders • Program 3: Amyotrophic Lateral Sclerosis and other neuromuscular disor- ders. During 2017 CIBERNED has consisted of 50 research groups supported by different universities, hospitals and the Research Council (CSIC), each led by a principal inves- tigator or responsible. CIBERNED is a network research center, composed of research groups belonging to different Administrations and affiliated Institutions: researcher members physically work in their parent institutions they belong to while simultane- ously and actively participating on CIBERNED’s own cooperative research agenda. It should be noted that during 2018 the Carlos III Institute of Health convened, within its annual call for aid of the Strategic Action of Health (AES), the incorporation of new groups to the CIBERNED consortium. This call has allowed the incorporation of 6 new groups (a new group for Program 1, another for Program 2 and four new groups for Program 3). 7 Thus, it is the result of a collaborative partnership between different institutions and the sum of 50 research groups. Depending on the results of the scientific evaluation of the various research groups, there is the possibility to agree on the discontinuation of some groups. Depending on budget availability, it may also consider adding some new research group currently outside CIBERNED that satisfy the requirements of scientific quality and translational activity and aligns with CIBERNED priorities. The Scientific Director Office has been set since October 2011 at the Center for Molecular Biology “Severo Ochoa” (CSIC) in Madrid. The headquarters, including the General Manag- er Office
Load more

Recommended publications
  • Analysis of Drugs Manual September 2019
    Drug Enforcement Administration Office of Forensic Sciences Analysis of Drugs Manual September 2019 Date Posted: 10/23/2019 Analysis of Drugs Manual Revision: 4 Issue Date: September 5, 2019 Effective Date: September 9, 2019 Approved By: Nelson A. Santos Table of Contents CHAPTER 1 – QUALITY ASSURANCE ......................................................................... 3 CHAPTER 2 – EVIDENCE ANALYSIS ......................................................................... 93 CHAPTER 3 – FIELD ASSISTANCE .......................................................................... 165 CHAPTER 4 – FINGERPRINT AND SPECIAL PROGRAMS ..................................... 179 Appendix 1A – Definitions ........................................................................................... 202 Appendix 1B – Acronyms and Abbreviations .............................................................. 211 Appendix 1C – Instrument Maintenance Schedule ..................................................... 218 Appendix 1D – Color Test Reagent Preparation and Procedures ............................... 224 Appendix 1E – Crystal and Precipitate Test Reagent Preparation and Procedures .... 241 Appendix 1F – Thin Layer Chromatography................................................................ 250 Appendix 1G – Qualitative Method Modifications ........................................................ 254 Appendix 1H – Analytical Supplies and Services ........................................................ 256 Appendix 2A – Random Sampling Procedures
    [Show full text]
  • REVISTA BARÇA Presenta El Resultado De Un Trabajo De Meses
    0101_ok:FCB26 05/06/2008 10:48 Page 1 BARÇA Revista Oficial FC Barcelona · Junio del 2008 Núm. 33 · 3 Euros www.fcbarcelona.cat EL SEÑOR DEL BANQUILLO De Greenwell a Guardiola. La historia, el estilo y el entorno 0202_AUDI:SECCIONS FCB28 04/06/2008 11:07 Page 2 0303:EDITORIAL FCB28 05/06/2008 17:26 Page 3 BARÇA EDITORIAL Revista Oficial FC Barcelona · Junio del 2008 Núm. 33 · 3 Euros www.fcbarcelona.cat EL SEÑOR DEL BANQUILLO De Greenwell a Guardiola. La historia, el estilo y el entorno JUNIO DEL 2008 50 para ser grandes como somos Edita: Futbol Club Barcelona 49 en 108 años de vida y Pep Guardiola es el que suma 50. Ésta es la cifra de entrena- Av. Arístides Maillol, s/n - 08028 Barcelona dores que el FC Barcelona ha tenido desde 1899. De un juego entre amigos se ha pasa- Telf. 9021899 00 - Fax 934112210 Dirección electrónica: [email protected] do a un deporte superprofesionalizado, y cada entrenador ha procurado dejar su huella. Algunos han hecho historia de verdad, la que se escribe con títulos, haciendo que arrai- Director: Jordi Badia. gase una forma de jugar generosa con el espectáculo, proponiendo un fútbol adecuado al paladar del público del Barça. Otros han trampeado situaciones complicadas –econó- Subdirectores: Eduard Pujol, Toni Ruiz micas, sociales o estrictamente deportivas–, presentando un balance de títulos más dis- y David Saura. creto, sobre todo de cuando la Liga estaba revestida de un valor épico que hoy ya no tiene. Este número 33 de la REVISTA BARÇA presenta el resultado de un trabajo de meses.
    [Show full text]
  • Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma
    cells Article Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma Tamara T. Lah 1,2,3,*, Metka Novak 1, Milagros A. Pena Almidon 4, Oliviero Marinelli 4 , Barbara Žvar Baškoviˇc 1, Bernarda Majc 1,3, Mateja Mlinar 1, Roman Bošnjak 5, Barbara Breznik 1 , Roby Zomer 6 and Massimo Nabissi 4 1 Department of Genetic Toxicology and Cancer Biology, National Institute of Biology, 1000 Ljubljana, Slovenia; [email protected] (M.N.); [email protected] (B.Ž.B.); [email protected] (B.M.); [email protected] (M.M.); [email protected] (B.B.) 2 Faculty of Chemistry and Chemical Technology, University of Ljubljana, 1000 Ljubljana, Slovenia 3 Jožef Stefan International Postgraduate School, 1000 Ljubljana, Slovenia 4 School of Pharmacy, Experimental Medicine Section, University of Camerino, 62032 Camerino, Italy; [email protected] (M.A.P.A.); [email protected] (O.M.); [email protected] (M.N.) 5 Department of Neurosurgery, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia; [email protected] 6 MGC Pharmaceuticals d.o.o., 1000 Ljubljana, Slovenia; [email protected] * Correspondence: [email protected]; Tel.: +386-41-651-629 Simple Summary: Among primary brain tumours, glioblastoma is the most aggressive. As early relapses are unavoidable despite standard-of-care treatment, the cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) alone or in combination have been suggested as a combined treatment strategy for glioblastomas. However, the known psychoactive effects of THC hamper its medical applications in these patients with potential cognitive impairment due to the progression of the Citation: Lah, T.T.; Novak, M.; Pena Almidon, M.A.; Marinelli, O.; disease.
    [Show full text]
  • A Dissertation Entitled Uncovering Cannabinoid Signaling in C. Elegans
    A Dissertation Entitled Uncovering Cannabinoid Signaling in C. elegans: A New Platform to Study the Effects of Medicinal Cannabis By Mitchell Duane Oakes Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Doctor of Philosophy Degree in Biology ________________________________________ Dr. Richard Komuniecki, Committee Chair _______________________________________ Dr. Bruce Bamber, Committee Member ________________________________________ Dr. Patricia Komuniecki, Committee Member ________________________________________ Dr. Robert Steven, Committee Member ________________________________________ Dr. Ajith Karunarathne, Committee Member ________________________________________ Dr. Jianyang Du, Committee Member ________________________________________ Dr. Amanda Bryant-Friedrich, Dean College of Graduate Studies The University of Toledo August 2018 Copyright 2018, Mitchell Duane Oakes This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of Uncovering Cannabinoid Signaling in C. elegans: A New Platform to Study the Effects of Medical Cannabis By Mitchell Duane Oakes Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Doctor of Philosophy Degree in Biology The University of Toledo August 2018 Cannabis or marijuana, a popular recreational drug, alters sensory perception and exerts a range of medicinal benefits. The present study demonstrates that C. elegans exposed to
    [Show full text]
  • Microgram Journal, Vol 2, Number 1
    Washington, D. C. Office of Science and Education Vol.II,No.1 Division of Laboratory Operations January 1969 INDEXISSUE CORRECTION 11 "Structure Elucidation of 'LBJ' , by Sander W. Bellman, John W. Turczan, James Heagy and Ted M. Hopes, Micro­ Gram .!., 3, 6-13 (Dec. 1968) Page 7, third and fourth sentences under Discussion: Change to read: "The melting point of the acid moiety found in step (g) was 148-150°c., compared to the litera­ ture, v~lue of 151°c for the melting point of benzilic acid (2); thus the benzilic acid melting point gives support to the proposed structure for 'LBJ'. Spectral evidence also supports the proposed structure". MICRO-GRAMREVISION Please re-number the pages of your copies of Micro-Gram, Volume I. Re-number pages bearing printing only. Vol­ ume I will then be numbered from page 1, the front page of issue No. 1, through page 189 the last page of issue No. 12. To help with this task, pages contained within each issue are as follows: Issue Number Page Through 1 1 8 2 9 29 3 30 32 4 33 66 5 67 79 6 80 97 7 98 120 8 121 128 9 129 136 10 137 157 11 158 170 12 171 189 CAUTION: Use of this publication should be restricted to forensic analysts or others having a legitimate need for this material. From the Archive Library of Erowid Center http://erowid.org/library/periodicals/microgram -2- CANNABIS ,·,-...__/' Attached is a copy of 11A Short Rapid Method for the Identification of Cannabis." The method was developed by Mro H.D.
    [Show full text]
  • Tuning Drug Release from Polyoxazoline-Drug Conjugates T ⁎ J
    European Polymer Journal 120 (2019) 109241 Contents lists available at ScienceDirect European Polymer Journal journal homepage: www.elsevier.com/locate/europolj Tuning drug release from polyoxazoline-drug conjugates T ⁎ J. Milton Harrisa, ,1, Michael D. Bentleya, Randall W. Moreaditha, Tacey X. Viegasa,1, Zhihao Fanga, Kunsang Yoona, Rebecca Weimera, Bekir Dizmanb, Lars Nordstiernac a Serina Therapeutics, Inc., 601 Genome Way, Suite 2001, Huntsville, AL 35806, USA2 b Sabanci University, Faculty of Engineering and Natural Sciences, Tuzla, 34956 İstanbul, Turkey2 c Department of Chemistry and Chemical Engineering, Chalmers University of Technology, SE-412 96 Göteborg, Sweden ARTICLE INFO ABSTRACT Keywords: Poly(2-oxazoline)-drug conjugates with drugs attached via releasable linkages are being developed for drug Poly(2-oxazoline) or POZ delivery. Such conjugates with pendent ester linkages that covalently bind drugs to the polymer backbone ex- Poly(2-ethyl-2-oxazoline) or PEOZ hibit significantly slower hydrolytic release rates in plasma than the corresponding PEG- and dextran-drug Pendent drugs conjugates. The slow drug release rates in-vitro of these POZ-drug conjugates contribute to extended in-vivo Degradable ester linkages pharmacokinetic profiles. In some instances, the release kinetics may be relatively sustained and ideal foronce-a- Pharmacokinetics week subcutaneous injection, whereas the native drug by itself may only have an in-vivo half-life of a few hours. Drug delivery Phenolic drugs The origin of this unusual kinetic and pharmacokinetic behavior is proposed here to involve folding of the POZ conjugate such that the relatively hydrophobic drug forms a central core, and the relatively hydrophilic polymer wraps around the core and slows enzymatic attack on the drug-polymer chemical linkage.
    [Show full text]
  • Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back
    International Journal of Molecular Sciences Review Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back Osnat Almogi-Hazan * and Reuven Or Laboratory of Immunotherapy and Bone Marrow Transplantation, Hadassah Medical Center, The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel; [email protected] * Correspondence: [email protected] Received: 21 May 2020; Accepted: 19 June 2020; Published: 23 June 2020 Abstract: The Cannabis plant contains numerous components, including cannabinoids and other active molecules. The phyto-cannabinoid activity is mediated by the endocannabinoid system. Cannabinoids affect the nervous system and play significant roles in the regulation of the immune system. While Cannabis is not yet registered as a drug, the potential of cannabinoid-based medicines for the treatment of various conditions has led many countries to authorize their clinical use. However, the data from basic and medical research dedicated to medical Cannabis is currently limited. A variety of pathological conditions involve dysregulation of the immune system. For example, in cancer, immune surveillance and cancer immuno-editing result in immune tolerance. On the other hand, in autoimmune diseases increased immune activity causes tissue damage. Immuno-modulating therapies can regulate the immune system and therefore the immune-regulatory properties of cannabinoids, suggest their use in the therapy of immune related disorders. In this contemporary review, we discuss the roles of the endocannabinoid system in immunity and explore the emerging data about the effects of cannabinoids on the immune response in different pathologies. In addition, we discuss the complexities of using cannabinoid-based treatments in each of these conditions.
    [Show full text]
  • The Use of Cannabinoids in Animals and Therapeutic Implications for Veterinary Medicine: a Review
    Veterinarni Medicina, 61, 2016 (3): 111–122 Review Article doi: 10.17221/8762-VETMED The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a review L. Landa1, A. Sulcova2, P. Gbelec3 1Faculty of Medicine, Masaryk University, Brno, Czech Republic 2Central European Institute of Technology, Masaryk University, Brno, Czech Republic 3Veterinary Hospital and Ambulance AA Vet, Prague, Czech Republic ABSTRACT: Cannabinoids/medical marijuana and their possible therapeutic use have received increased atten- tion in human medicine during the last years. This increased attention is also an issue for veterinarians because particularly companion animal owners now show an increased interest in the use of these compounds in veteri- nary medicine. This review sets out to comprehensively summarise well known facts concerning properties of cannabinoids, their mechanisms of action, role of cannabinoid receptors and their classification. It outlines the main pharmacological effects of cannabinoids in laboratory rodents and it also discusses examples of possible beneficial use in other animal species (ferrets, cats, dogs, monkeys) that have been reported in the scientific lit- erature. Finally, the article deals with the prospective use of cannabinoids in veterinary medicine. We have not intended to review the topic of cannabinoids in an exhaustive manner; rather, our aim was to provide both the scientific community and clinical veterinarians with a brief, concise and understandable overview of the use of cannabinoids in veterinary
    [Show full text]
  • Pharmacodynamics of Cannabinoids
    Open Access Archives of Pharmacy and Pharmaceutical Sciences Review Article Pharmacodynamics of cannabinoids Alexandra Sulcova* ISSN ICCI - International Cannabis and Cannabinoids Institute, Jachymova 26/2, 110 00 Praha, 2639-992X Czech Republic “Pharmacodynamics of cannabinoids “(i.e. a set of biological effects elicited in the *Address for Correspondence: Alexandra Sulcova, M.D, Ph.D, Professor of Pharmacology, living organism by interaction with its biochemical and biophysical functions up to the FCMA, FECNP, FCINP, ICCI - International cellular level) is studied for a long time during both, physiological and pathological Cannabis and Cannabinoids Institute, Jachymova conditions. Cannabinoids received their names according to their natural occurrence 26/2, 110 00 Praha, Czech Republic, Tel: 420 732167678; Email: [email protected] as constituents of Cannabis sativa L. (marijuana). The species was classiied in the “Linnaeus’s Species Plantarum (1753)”, the word “sativa” means things that are Submitted: 12 April 2019 Approved: 07 May 2019 cultivated [1]. For ages, people have used cannabis-based preparations for healing and Published: 08 May 2019 pain suppression until the discovery (in 1897) of aspirin (acetylsalicylic acid) which contemporary medicine uses until today. Chemical investigation of marijuana conirmed Copyright: © 2019 Sulcova A. This is an open access article distributed under the Creative various cannabinoid-type components called cannabinoids (presently estimated at Commons Attribution License, which permits about 150). Regarding their possible pharmacodynamic effects, tetrahydrocannabinol unrestricted use, distribution, and reproduction (THC) and cannabidiol (CBD) are the most explored. The determination of THC structure in any medium, provided the original work is properly cited by means of nuclear magnetic resonance imaging increased sharply the number of professional scientiic reports dealing with the studies of THC pharmacodynamic mechanisms of action [2].
    [Show full text]
  • Icrs2015 Programme
    TH 25 ANNUAL SYMPOSIUM OF THE INTERNATIONAL CANNABINOID RESEARCH SOCIETY WOLFVILLE NOVA SCOTIA JUNE 28 - JULY 3, 2015 TH 25 ANNUAL SYMPOSIUM OF THE INTERNATIONAL CANNABINOID RESEARCH SOCIETY WOLFVILLE JUNE 28 – JULY 3, 2015 Symposium Programming by Cortical Systematics LLC Copyright © 2015 International Cannabinoid Research Society Research Triangle Park, NC USA ISBN: 978-0-9892885-2-1 These abstracts may be cited in the scientific literature as follows: Author(s), Abstract Title (2015) 25th Annual Symposium on the Cannabinoids, International Cannabinoid Research Society, Research Triangle Park, NC, USA, Page #. Funding for this conference was made possible in part by grant 5R13DA016280-13 from the National Institute on Drug Abuse. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government. Sponsors ICRS Government Sponsors National Institute on Drug Abuse Non- Profit Organization Sponsors Kang Tsou Memorial Fund 2015 ICRS Board of Directors Executive Director Cecilia Hillard, Ph.D. President Stephen Alexander, Ph.D. President- Elect Michelle Glass, Ph.D. Past President Ethan Russo, M.D. Secretary Steve Kinsey, Ph.D. Treasurer Mary Abood, Ph.D. International Secretary Roger Pertwee, D . Phil. , D . S c. Student Representative Tiffany Lee, Ph.D. Grant PI Jenny Wiley, Ph.D. Managing Director Jason Schechter, Ph.D. 2015 Symposium on the Cannabinoids Conference Coordinators Steve Alexander, Ph.D. Cecilia Hillard, Ph.D. Mary Lynch, M.D. Jason Schechter, Ph.D.
    [Show full text]
  • NIDA Drug Supply Program Catalog, 25Th Edition
    RESEARCH RESOURCES DRUG SUPPLY PROGRAM CATALOG 25TH EDITION MAY 2016 CHEMISTRY AND PHARMACEUTICS BRANCH DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES NATIONAL INSTITUTE ON DRUG ABUSE NATIONAL INSTITUTES OF HEALTH DEPARTMENT OF HEALTH AND HUMAN SERVICES 6001 EXECUTIVE BOULEVARD ROCKVILLE, MARYLAND 20852 160524 On the cover: CPK rendering of nalfurafine. TABLE OF CONTENTS A. Introduction ................................................................................................1 B. NIDA Drug Supply Program (DSP) Ordering Guidelines ..........................3 C. Drug Request Checklist .............................................................................8 D. Sample DEA Order Form 222 ....................................................................9 E. Supply & Analysis of Standard Solutions of Δ9-THC ..............................10 F. Alternate Sources for Peptides ...............................................................11 G. Instructions for Analytical Services .........................................................12 H. X-Ray Diffraction Analysis of Compounds .............................................13 I. Nicotine Research Cigarettes Drug Supply Program .............................16 J. Ordering Guidelines for Nicotine Research Cigarettes (NRCs)..............18 K. Ordering Guidelines for Marijuana and Marijuana Cigarettes ................21 L. Important Addresses, Telephone & Fax Numbers ..................................24 M. Available Drugs, Compounds, and Dosage Forms ..............................25
    [Show full text]
  • Barcelona Versus Real Madrid ‘Een Boek!’
    Barcelona versus Real Madrid ‘Een boek!’ Voor Claire en Charlie Espanyolito que vienes al mundo te guarde Dios Una de las dos Españas Ha de helarte el corazón. Kleine Spanjaard die ter wereld komt Moge God je behoeden een van beide Spanjes zal je hart verkillen. Antonio MAchAdo Madrid of Barcelona? Oviedo. Michu inhoudsopgAve Woord vooraf 7 valuta en taal 9 1 – De dag erna 11 2 – De avond ervoor 13 3 – De voorzitter-martelaar 35 4 – De vergeten voorzitter 49 5 – Duivelbezwering 68 6 – Don Santiago 93 7 – Het huis dat László bouwde 107 8 – Het contract van de eeuw 127 9 – Blonde pijl 148 10 – HH: de originele Special One 168 11 – De beste ambassade die we ooit gehad hebben 193 12 – De fluitist 219 13 – Johan Cruijff Superstar 238 14 – De vijf van de gier 267 15 – Dreamteam 291 16 – Nunca positifo 324 17 – Tweeëndertig jaar later 342 18 – En de varkens vlogen wel degelijk 362 19 – De ballenjongen en de vertaler 393 dankwoord 435 Bibliografie 438 Register 443 WooRd VOORAF Honderden bladzijden en duizenden woorden: het lijkt hier wel de vloer van een montagekamer. Sinds ik begon te schrijven is dit boek geëvolueerd en veranderd. Sinds de eerste versie is het ook drastisch ingekort. Het is vooral gebaseerd op archiefmateriaal dat vaak een nieuw licht op de rivaliteit heeft geworpen en op een lange reeks interviews die ik de laatste jaren heb gevoerd met spe- lers, coaches, bestuursleden en voorzitters van Real Madrid en FC Barcelona. Gaandeweg is het haast oral history geworden en ik wil iedereen danken die zo gul tijd voor me heeft vrijgemaakt
    [Show full text]